Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

COVID-19 risk | Multiple Sclerosis News Today | illustration of cells

Acthar Gel (Repository Corticotropin Injection) for Multiple Sclerosis

Last updated May 18, 2022, by Teresa Carvalho, MS

Fact-checked by Patricia Silva, PhD

FAQs about Acthar Gel

Acthar Gel was approved by the U.S. Food and Drug Administration in the 1970s for the treatment of multiple sclerosis. It was re-approved in 2010. The medicine had originally been approved in the U.S. in 1952 for several conditions, such as collagen diseases, inflammatory diseases of the skin and the eye, metabolic disorders, and allergic states, among others.

Acthar Gel may cause harm to a developing fetus. Patients should talk with their healthcare team and only continue Acthar Gel during pregnancy if the potential benefits justify the possible risks to the fetus.

The prescribing information for Acthar Gel does not report a direct interaction between the medication and alcohol. However, given that alcohol can interfere with some medications and disease symptoms, patients are advised to discuss this topic with their healthcare provider.

According to Mallinckrodt Pharmaceuticals, which markets Acthar Gel, patients with multiple sclerosis (MS) taking the therapy reported clinically significant improvements in physical and psychological status after two months of treatment. These improvements were maintained six months after starting the medication. An improvement in MS-related eye problems, namely visual impairment due to optic neuritis, also was reported in patients after 15 days of treatment with Acthar Gel. Nonetheless, it is important to keep in mind that each patient may respond to treatment in a different way.

Changes in body weight may occur. Patients who develop Cushing’s syndrome while on Acthar Gel may have greater deposits of fat resulting in weight gain; however, this usually resolves after therapy is stopped. Hair loss has not been reported as a side effect in people taking Acthar Gel. Patients should be monitored for these signs and should report any such symptoms to their healthcare providers.

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Related Articles


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.